Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Merck
AstraZeneca
Express Scripts
Moodys

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REMIFENTANIL HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Remifentanil Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00158873 Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects Completed GlaxoSmithKline Phase 4 2004-09-01 The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.
NCT00162591 Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl Unknown status Assistance Publique - Hôpitaux de Paris N/A 2004-10-01 The aim of this protocol is to study the prophylactic effect of remifentanil on bispectral index variation during a nociceptive stimuli.
NCT00202722 Remifentanil as Intravenous Patient-controlled Analgesia (IVPCA) During Labour Completed Sorlandet Hospital HF Phase 4 2004-01-01 Remifentanil is a ultra short-acting synthetic opioid. It is rapidly metabolized by non-specific blood and tissue esterases. We wanted to investigate the efficacy and safety of remifentanil used as analgesia during labour. Intravenous patient controlled analgesia (ivpca) were used to administer remifentanil. Doses used were 0,15-1,05 mikrogr/kg, with a lock-out time of 2 minutes. 41 women were included in the study. Blood-pressure, heartrate, SaO2, respiration rate and sedation were recorded every 15.minute. Fetal heart rate was recorded for the whole periode of treatment (CTG, STAN). Vaginal contraction pain were assessed by the parturients every 15.minute using a Visual Analogue Scale (VAS). Midwives also recorded their impression of the parturients pain. The parturients level of sedation were recorded by anesthesiologist and midwife every 15.minute. Apgar scores were registered at 1, 5 and 10 min after delivery. Umbilical cord blood analysis regarding blood gases and concentration of remifentanil were performed. After delivery, both mother and midwife evaluated efficacy and safety; Global satisfaction score, if the remifentanil doses were sufficient, nausea, vomiting, level of sedation and dizziness.
NCT00209872 Optimal Multimodal Analgesia in Abdominal Hysterectomy Unknown status Hvidovre University Hospital Phase 4 2005-10-01 The purpose of this study is to test the current standard of care (SOC) treatment for abdominal hysterectomy with a group receiving SOC minus epidural analgesia plus additional perioperative analgesics in terms of postoperative abilities, postoperative nausea and vomiting (PONV), pain and discharge time from the PACU (post-anaesthesia care unit).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Remifentanil Hydrochloride

Condition Name

Condition Name for Remifentanil Hydrochloride
Intervention Trials
Anesthesia 67
Pain 36
Postoperative Pain 27
Pain, Postoperative 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Remifentanil Hydrochloride
Intervention Trials
Pain, Postoperative 46
Hyperalgesia 20
Postoperative Nausea and Vomiting 14
Vomiting 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Remifentanil Hydrochloride

Trials by Country

Trials by Country for Remifentanil Hydrochloride
Location Trials
Korea, Republic of 93
United States 57
France 42
China 33
Canada 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Remifentanil Hydrochloride
Location Trials
Ohio 10
Illinois 8
New York 6
Texas 6
Massachusetts 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Remifentanil Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Remifentanil Hydrochloride
Clinical Trial Phase Trials
Phase 4 226
Phase 3 40
Phase 2/Phase 3 7
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Remifentanil Hydrochloride
Clinical Trial Phase Trials
Completed 263
Recruiting 102
Not yet recruiting 68
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Remifentanil Hydrochloride

Sponsor Name

Sponsor Name for Remifentanil Hydrochloride
Sponsor Trials
Yonsei University 29
Ajou University School of Medicine 16
Hopital Foch 12
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Remifentanil Hydrochloride
Sponsor Trials
Other 634
Industry 38
U.S. Fed 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
McKesson
Baxter
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.